Safety and Tolerability of Glatiramer Acetate
Public ClinicalTrials.gov record NCT01874145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared to GA 20 mg/mL every day (QD) administered SC.
Study identification
- NCT ID
- NCT01874145
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 209 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2013 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Jan 14, 2016
2013 – 2014
United States locations
- U.S. sites
- 35
- U.S. states
- 18
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10706 | Cullman | Alabama | — | — |
| Teva Investigational Site 10719 | Gilbert | Arizona | — | — |
| Teva Investigational Site 10720 | Phoenix | Arizona | — | — |
| Teva Investigational Site 10727 | Fresno | California | — | — |
| Teva Investigational Site 10731 | Long Beach | California | — | — |
| Teva Investigational Site 10735 | Newport Beach | California | — | — |
| Teva Investigational Site 10712 | Oceanside | California | — | — |
| Teva Investigational Site 10708 | Centennial | Colorado | — | — |
| Teva Investigational Site 10715 | Maitland | Florida | — | — |
| Teva Investigational Site 10718 | Pompano Beach | Florida | — | — |
| Teva Investigational Site 10709 | St. Petersburg | Florida | — | — |
| Teva Investigational Site 10707 | Tampa | Florida | — | — |
| Teva Investigational Site 10711 | Tampa | Florida | — | — |
| Teva Investigational Site 10710 | Northbrook | Illinois | — | — |
| Teva Investigational Site 10734 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 10732 | Baltimore | Maryland | — | — |
| Teva Investigational Site 10726 | Great Falls | Montana | — | — |
| Teva Investigational Site 10702 | Henderson | Nevada | — | — |
| Teva Investigational Site 10717 | Patchogue | New York | — | — |
| Teva Investigational Site 10723 | Plainview | New York | — | — |
| Teva Investigational Site 10716 | Charlotte | North Carolina | — | — |
| Teva Investigational Site 10724 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 10721 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 10733 | Bellevue | Ohio | — | — |
| Teva Investigational Site 10703 | Columbus | Ohio | — | — |
| Teva Investigational Site 10714 | Dayton | Ohio | — | — |
| Teva Investigational Site 10704 | Uniontown | Ohio | — | — |
| Teva Investigational Site 10725 | East Providence | Rhode Island | — | — |
| Teva Investigational Site 10736 | Cordova | Tennessee | — | — |
| Teva Investigational Site 10701 | Franklin | Tennessee | — | — |
| Teva Investigational Site 10728 | Nashville | Tennessee | — | — |
| Teva Investigational Site 10729 | Mansfield | Texas | — | — |
| Teva Investigational Site 10722 | Round Rock | Texas | — | — |
| Teva Investigational Site 10699 | Salt Lake City | Utah | — | — |
| Teva Investigational Site 10700 | Roanoke | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01874145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2016 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01874145 live on ClinicalTrials.gov.